(JDOC) JPMorgan Healthcare Leaders - Ratings and Ratios
Exchange: NASDAQ •
Country: USA •
Currency: USD •
Type: Etf •
ISIN: US46654Q7658
Pharmaceutical, Biotechnology, Healthcare Services, Medical Technology, Life Sciences
Description: JDOC JPMorgan Healthcare Leaders
The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.
Additional Sources for JDOC ETF
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
JDOC ETF Overview
| Market Cap in USD | 8m |
| Category | Health |
| TER | 0.65% |
| IPO / Inception | 2023-11-01 |
JDOC ETF Ratings
| Growth Rating | -5.97 |
| Fundamental | - |
| Dividend Rating | 55.4 |
| Rel. Strength | -18.8 |
| Analysts | - |
| Fair Price Momentum | 59.20 USD |
| Fair Price DCF | - |
JDOC Dividends
| Dividend Yield 12m | 5.38% |
| Yield on Cost 5y | 6.10% |
| Annual Growth 5y | 493.40% |
| Payout Consistency | 66.7% |
| Payout Ratio | % |
JDOC Growth Ratios
| Growth Correlation 3m | 8.8% |
| Growth Correlation 12m | -85.9% |
| Growth Correlation 5y | -6.4% |
| CAGR 5y | 5.67% |
| CAGR/Max DD 5y | 0.27 |
| Sharpe Ratio 12m | 0.76 |
| Alpha | -17.05 |
| Beta | 0.508 |
| Volatility | 12.89% |
| Current Volume | 0.1k |
| Average Volume 20d | 0.1k |
What is the price of JDOC shares?
As of July 06, 2025, the stock is trading at USD 50.60 with a total of 100 shares traded.
Over the past week, the price has changed by +0.60%, over one month by +1.36%, over three months by +2.21% and over the past year by -8.40%.
As of July 06, 2025, the stock is trading at USD 50.60 with a total of 100 shares traded.
Over the past week, the price has changed by +0.60%, over one month by +1.36%, over three months by +2.21% and over the past year by -8.40%.
Is JPMorgan Healthcare Leaders a good stock to buy?
Neither. Based on ValueRay´s Analyses, JPMorgan Healthcare Leaders is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -5.97 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JDOC is around 59.20 USD . This means that JDOC is currently undervalued and has a potential upside of +17% (Margin of Safety).
Neither. Based on ValueRay´s Analyses, JPMorgan Healthcare Leaders is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -5.97 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JDOC is around 59.20 USD . This means that JDOC is currently undervalued and has a potential upside of +17% (Margin of Safety).
Is JDOC a buy, sell or hold?
JPMorgan Healthcare Leaders has no consensus analysts rating.
JPMorgan Healthcare Leaders has no consensus analysts rating.
What are the forecasts for JDOC share price target?
According to our own proprietary Forecast Model, JDOC JPMorgan Healthcare Leaders will be worth about 66.5 in July 2026. The stock is currently trading at 50.60. This means that the stock has a potential upside of +31.5%.
According to our own proprietary Forecast Model, JDOC JPMorgan Healthcare Leaders will be worth about 66.5 in July 2026. The stock is currently trading at 50.60. This means that the stock has a potential upside of +31.5%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 66.5 | 31.5% |